Evidence map›Paper›PMID 36183289›Full record

ReviewWorld journal of urology2023

Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.

Igor Tsaur, Roman A Blaheta, Robert Dotzauer, Maximilian P Brandt, Giorgio Gandaglia, Ioanel Sinescu, Cristian Mirvald, Jonathan Olivier, Cristian Surcel, EAU-YAU Prostate Cancer Working Party

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Igor Tsaur *Department of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Roman A Blaheta *Department of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Robert Dotzauer *Department of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Maximilian P BrandtDepartment of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Giorgio GandagliaDivision of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Ioanel SinescuCenter of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, 00238, Bucharest, Romania.
Cristian Mirvald *Center of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, 00238, Bucharest, Romania.
Jonathan Olivier *Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France.
Cristian Surcel *Center of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, 00238, Bucharest, Romania. drsurcel@gmail.com.
EAU-YAU Prostate Cancer Working Party
Johannes Gutenberg University Mainz · DECarol Davila University of Medicine and Pharmacy · ROCentre National de la Recherche Scientifique · FRIRCCS Ospedale San Raffaele · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFocal therapy (FT) is gaining increasing acceptance in the management of localized prostate cancer particularly due to its favorable safety. Preliminary evidence suggests advantageous utilization of local treatment in the field of oligometastatic prostate cancer (OMPC). Since data on the utilization of FT in OMPC are scarce, we sought to summarize available evidence.

methodsFor this narrative comprehensive review, we employed PubMed

resultsGrowing evidence points to distinct differences in the biologic behavior and molecular signaling processes of OMPC as compared to polymetastatic disease (PMPC). No established biomarkers are available to accurately identify OMPC yet, while several candidates are currently under investigation. The evolution of molecular imaging is set to aid in selecting patients benefitting most from local management. Differences between OMPC and PMPC should be considered when designing the optimal therapeutic strategy. While efficacy data for FT in comparison to standard care in OMPC are scarce, longer progression-free survival and time to castration resistance have been demonstrated for bone metastatic prostate cancer with the primary tumor treated by cryosurgery followed by androgen deprivation therapy (ADT) compared to ADT alone.

conclusionOngoing research efforts are eagerly awaited to better characterize OMPC and establish customized strategies for patients with this condition.

Indexed as

Prostatic NeoplasmsAndrogen AntagonistsHumansMaleAndrogen AntagonistsAblationFocal therapyHormone-sensitiveOligometastaticProstate cancer

Identifiers

PMID36183289
OpenAlexW4298858023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.